MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Mind Medicine (MindMed) Inc.
One World Trade Center
New York, NY 10007
Maxim Jacobs, CFA
Vice President, Investor Relations and Corporate Communications
Computershare Investor Services
100 University Ave.
8th Floor, North Tower
Toronto, Ontario M5J2Y1
T: 1-800-564-6253 (toll free in Canada and US)
T: 514-982-7555 (international direct dial)